Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Matched targeted therapy for paediatric patients with relapsed, refractory or...

Dr Yana Pikman - Dana Farber Cancer Institute, Boston, USA

$Matched targeted therapy for paediatric patients with relapsed, refractory or high-risk leukemias ( Dr Yana Pikman - Dana Farber Cancer Institute, Boston, USA )$

ECHELON-2: Study into brentuximab vedotin and CHP versus CHOP in the frontline...

Dr Lorenz Trümper - Georg August University, Göttingen, Germany

ECHELON-2: Study into brentuximab vedotin and CHP versus CHOP in the frontline treatment of patients with T-Cell lymphomas ( Dr Lorenz Trümper - Georg August University, Göttingen, Germany )

KRd versus VRd in patients with newly diagnosed multiple myeloma

Dr Ola Landgren - Memorial Sloan Kettering Cancer Centre, New York, USA

KRd versus VRd in patients with newly diagnosed multiple myeloma ( Dr Ola Landgren - Memorial Sloan Kettering Cancer Centre, New York, USA )

Landscape change with oral proteasome maintenance in multiple myeloma patients

Prof Maria-Victoria Mateos, Prof Wee Joo Chng, Prof Meral Beksac and Dr Sagar...

Landscape change with oral proteasome maintenance in multiple myeloma patients ( Prof Maria-Victoria Mateos, Prof Wee Joo Chng, Prof Meral Beksac and Dr Sagar Lonial )

Multiple myeloma highlights and more from ASH 2018

Prof Mohamad Mohty - Saint-Antoine Hospital, Paris, France

Multiple myeloma highlights and more from ASH 2018 ( Prof Mohamad Mohty - Saint-Antoine Hospital, Paris, France )

The benefits of a stem cell transplant after CAR T-cell therapy in paediatric...

Dr Corinne Summers - Seattle Children's Hospital, Seattle, USA

The benefits of a stem cell transplant after CAR T-cell therapy in paediatric patients ( Dr Corinne Summers - Seattle Children's Hospital, Seattle, USA )

ACT-1: Addition of alemtuzumab to a CHOP backbone for young patients with T...

Dr Owen O'Connor - Columbia University Medical Centre, New York, USA

ACT-1: Addition of alemtuzumab to a CHOP backbone for young patients with T-cell lymphoma ( Dr Owen O'Connor - Columbia University Medical Centre, New York, USA )

Ibrutinib alone and in combination with rituximab for older patients with...

Dr Jennifer Woyach - The Ohio State University Comprehensive Cancer Centre...

Ibrutinib alone and in combination with rituximab for older patients with chronic lymphocytic leukaemia ( Dr Jennifer Woyach - The Ohio State University Comprehensive Cancer Centre, Columbus, USA )

Improving toxicity and outcomes by taking ibrutinib during and after CAR T-cell...

Dr Jordan Gauthier - Fred Hutchinson Cancer Research Centre, Seattle, USA

$Improving toxicity and outcomes by taking ibrutinib during and after CAR T-cell therapy for relapsed and/or refractory CLL ( Dr Jordan Gauthier - Fred Hutchinson Cancer Research Centre, Seattle, USA )$

CD19-directed CAR T-cell therapy for patients with relapsed B-cell acute...

Dr Shannon Maude - Children’s Hospital of Philadelphia, Philadelphia, USA

CD19-directed CAR T-cell therapy for patients with relapsed B-cell acute lymphocytic leukaemia ( Dr Shannon Maude - Children’s Hospital of Philadelphia, Philadelphia, USA )

Young SIOG attendees and and the latest CDK inhibitors research in breast cancer

Nicolò Battisti - The Royal Marsden NHS Foundation Trust, London, UK

Young SIOG attendees and and the latest CDK inhibitors research in breast cancer ( Nicolò Battisti - The Royal Marsden NHS Foundation Trust, London, UK )

Breast cancer highlights from ESMO 2018

Dr Matteo Lambertini - Institut Jules Bordet, Brussels, Belgium

Breast cancer highlights from ESMO 2018 ( Dr Matteo Lambertini - Institut Jules Bordet, Brussels, Belgium )

More from ecancer